Q1 Earnings Estimate for TSE:ONC Issued By Zacks Research

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS and Q4 2026 earnings at ($0.08) EPS.

Oncolytics Biotech Stock Performance

TSE ONC opened at C$14.90 on Thursday. Oncolytics Biotech has a 52-week low of C$0.44 and a 52-week high of C$2.08. The company has a 50-day simple moving average of C$14.90 and a 200 day simple moving average of C$14.90. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The company has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

Insider Activity

In related news, Director Bernd Robert Seizinger bought 60,000 shares of Oncolytics Biotech stock in a transaction dated Wednesday, February 11th. The stock was purchased at an average cost of C$1.14 per share, with a total value of C$68,400.00. Following the transaction, the director directly owned 526,991 shares of the company’s stock, valued at approximately C$600,769.74. The trade was a 12.85% increase in their ownership of the stock. Also, Director Wayne Pisano bought 30,000 shares of Oncolytics Biotech stock in a transaction dated Thursday, February 12th. The shares were bought at an average cost of C$1.16 per share, with a total value of C$34,800.00. Following the completion of the transaction, the director directly owned 288,306 shares in the company, valued at approximately C$334,434.96. This trade represents a 11.61% increase in their ownership of the stock. Over the last ninety days, insiders purchased 289,232 shares of company stock worth $335,760. 3.82% of the stock is owned by insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.